Ozge Saatci

7PUBLICATIONS
36CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 02, 2026
Sphingosine kinase-2 inhibition promotes immunogenic differentiation of myeloid-derived suppressor cells through an Acetyl-CoA carboxylase-phosphatidylcholine axis.

|Jun 15, 2024
Targeting LINC00152 activates cAMP/Ca2+/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer.

Ozge Saatci, Rashedul Alam, Kim-Tuyen Huynh-Dam

|May 27, 2024
HSP70-mediated mitochondrial dynamics and autophagy represent a novel vulnerability in pancreatic cancer.

Giulia D S Ferretti, Colleen E Quaas, Irene Bertolini

|Mar 18, 2024
Targeting LINC00152 activates cAMP/Ca2+/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer.

Ozge Saatci, Rashed Alam, Kim-Tuyen Huynh-Dam

|Feb 06, 2024
Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer.

Mustafa Emre Gedik, Ozge Saatci, Nathaniel Oberholtzer

|Nov 02, 2023
Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancer.

Ozge Saatci, Metin Cetin, Meral Uner

Pageof 2

Frequent Collaborators

5 joint publications

Ozgur Sahin

3 joint publications

Meral Uner

3 joint publications

Sercan Aksoy

2 joint publications

Ozge Akbulut Caliskan